---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-022228"
form_type: "8-K"
ticker: "XENE"
cik: "0001582313"
company_name: "Xenon Pharmaceuticals Inc."
filed_at: "2022-06-02T23:59:59+00:00"
generated_at: "2026-06-25T05:08:39.622108+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Xenon shareholders approve 5.3M share equity plan increase; all director nominees elected

## Summary
- Amendment to 2014 Equity Plan approved: 35.6M for, 6.2M against, 5.1M broker non-votes.
- Total share reserve under plan increased to ~13.37M shares (includes prior reserves and 5.3M addition).
- All eight director nominees elected with strong majority (e.g., Simon Pimstone 40.9M for).
- Say-on-pay advisory vote passed: 41.1M for, 0.6M against.
- KPMG reappointed as auditor with 45.9M for, 1.0M withheld.

## SEC filing metadata
- accession: 0001564590-22-022228
- form_type: 8-K
- ticker: XENE
- cik: 0001582313
- company_name: Xenon Pharmaceuticals Inc.
- filed_at: 2022-06-02T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1582313/000156459022022228/0001564590-22-022228-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1582313/000156459022022228/xene-8k_20220601.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-022228
- JSON: https://secwatch.observer/filing/0001564590-22-022228.json
- Plain text: https://secwatch.observer/filing/0001564590-22-022228.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.